FCM
ABEO icon

Farallon Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Farallon Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-80,000
Closed -$6.54M – 103
2019
Q4 		$6.54M Buy
+80,000
New +$5.64M 0.04% 105

Other funds holding ABEO

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Farallon Capital Management's ABEO Position: Q1 2020 in Review

Farallon Capital Management sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 80,000 shares — an estimated $6.54M sold.

Farallon Capital Management first reported a position in ABEO in Q4 2019 and held it in 1 quarter. The position peaked at $6.54M in Q4 2019. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

  • Farallon Capital Management reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Farallon Capital Management sold 80,000 Abeona Therapeutics shares in Q1 2020, an estimated $6.54M.
  • Farallon Capital Management first reported a position in Abeona Therapeutics in Q4 2019 and held it in 1 quarter.
  • Farallon Capital Management's Abeona Therapeutics position peaked at $6.54M in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.